Gamida Cell (NASDAQ:GMDA) Price Target Lowered to $5.00 at HC Wainwright

Gamida Cell (NASDAQ:GMDA) had its target price trimmed by HC Wainwright from $11.00 to $5.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Gamida Cell’s Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.66) EPS and FY2024 earnings at ($0.52) EPS.

GMDA has been the subject of several other reports. JMP Securities reaffirmed a market outperform rating and issued a $6.00 price objective on shares of Gamida Cell in a research note on Thursday, September 28th. Needham & Company LLC reaffirmed a buy rating and issued a $6.00 price objective on shares of Gamida Cell in a research note on Tuesday, August 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gamida Cell has a consensus rating of Buy and a consensus price target of $5.40.

Gamida Cell Price Performance

Shares of Gamida Cell stock opened at $0.31 on Wednesday. The stock has a 50 day moving average of $0.84 and a 200 day moving average of $1.36. Gamida Cell has a 12 month low of $0.26 and a 12 month high of $2.51. The firm has a market cap of $32.45 million, a PE ratio of -1.02 and a beta of 1.59. The company has a current ratio of 3.32, a quick ratio of 2.72 and a debt-to-equity ratio of 213.14.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Gamida Cell during the 1st quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Gamida Cell during the 2nd quarter valued at $29,000. Lazard Asset Management LLC bought a new stake in Gamida Cell during the 2nd quarter valued at $30,000. Jane Street Group LLC bought a new stake in Gamida Cell during the 4th quarter valued at $33,000. Finally, Qube Research & Technologies Ltd bought a new stake in Gamida Cell during the 3rd quarter valued at $34,000. 42.74% of the stock is currently owned by hedge funds and other institutional investors.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.